The Academy’s NIH Ranking Task Force
Professor Jason S. Lewis is the Emily Tow Jackson Chair in Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) and currently serves as Vice Chair for Research and as the Chief of the Radiochemistry & Imaging Sciences Service in MSKCC’s Department of Radiology. He is the Director of MSKCC’s Radiochemistry and Molecular Imaging Probe Core Facility and is Director of the MSKCC Center for Molecular Imaging & Nanotechnology. He is a Member in MSKCC, Laboratory Head in the Sloan-Kettering Institute’s Molecular Pharmacology and Chemistry Program, and a Professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences and at Weill-Cornell Medical College. Professor Lewis earned a B.Sc. in Chemistry (1992) and a M.Sc. (1993) in Chemistry from the University of Essex in the laboratory of Professor Jonathan R. Dilworth. He then obtained a Ph.D. in Biochemistry in 1996 from the University of Kent mentored by Professor Philip J. Blower. His postdoctoral work was with Professors Carolyn J. Anderson and Michael J. Welch at the Washington University School of Medicine (WUSM). Subsequently he joined the WUSM faculty as an Assistant Professor at the Mallinckrodt Institute of Radiology (2003- 2008). In 2008 he joined MSKCC. Professor Lewis serves on grant review panels for the National Institutes of Health/National Cancer Institute and on a number editorial boards. He was the President of the World Molecular Imaging Society (2014-2015). His research interests are focused on the development of new molecular imaging agents and radiopharmaceuticals for the diagnosis and treatment of cancer. He has worked on the development of small molecules targeting cancer, as well as radiolabeled peptides and Zr-89-labeled antibodies targeting disease-specific receptors and antigens; this is always with the ultimate goal of clinical translation. He has published over 150 papers, books, book chapters, and reviews in the field of molecular imaging.
Dr. Woodard received her undergraduate degree from Duke University in 1986 and her MD from the Duke University School of Medicine in 1990. She completed her internship in Internal Medicine at the University of North Carolina at Chapel Hill in 1991, and her residency in Diagnostic Radiology from Duke University in 1995.
Dr. Woodard leads her own research program and led one of the key projects on the Washington University NIH contract, Programs of Excellence in Nanotechnology (PEN) which developed a receptor-targeted radiotracer for atherosclerotic plaque imaging. She has over 160 manuscripts, federal and non-federal funding, several patents and has served on NIH study sections, including as a standing member on the study section Clinical and Integrative Cardiovascular Sciences (CICS). She currently is serving as a standing member on the NIH study section, Medical Imaging (MEDI). She has received numerous awards for her work including being named an Academy of Radiology Research Distinguished Investigator.
She is a member of many professional organizations, including the American College of Radiology (ACR), serving on the ACR commission on Research, the Radiological Society of North America (RSNA), International Society for Magnetic Resonance in Medicine (ISMRM), Society of Nuclear Medicine and Molecular Imaging (SNMMI), American Heart Association (AHA), Society for Cardiovascular Magnetic Resonance (SCMR) and Society for Cardiac Computed Tomography (SCCT). She is past president of the North American Society for Cardiovascular Imaging (NASCI). She is a Fellow of the American College of Radiology (FACR), American Heart Association (FAHA), American College of Chest Physicians (FCCP) and North American Society for Cardiovascular Imaging (FNASCI).
The NIH funding to diagnostic radiology has been reported annually since the early 90’s by Stanley Baum, MD. This information is tracked and shared by the Academy to show the amount of federal funding from the NIH that goes to diagnostic radiology as well as how much of that funding is allocated across Radiology Departments. Shown below is a chart depicting the history of this funding as reported by Dr. Baum between 1985 and 2017 (note the outlying increase in 2010 as a result of the American Recovery and Reinvestment Act). The raw data received from the NIH includes information on grants awarded to Principal Investigators (PI) with primary appointments in a Radiology Department at a US Medical School.
- The raw NIH data lists grants at Radiology Departments which are part of a University. Some NIH grants go through a Hospital, Foundation and not a University and therefore not on the initial list. The Chairs of Radiology at these Institutions ,i.e. MGH, BWH, Sloan Kettering, etc. are contacted to gather that information independently.
- The raw data is sorted as it often contains duplicate or sometimes incorrect information.
- The raw data from NIH includes grants in Radiation Oncology. Those grants are removed. However, grant applicants sometimes incorrectly categorize the grant under Radiation Oncology when it should be under Radiology. A manual review of all grants is made to address and correct such errors.
- Identification is made of all PI’s in Radiology Departments who perform their research outside of the Hospital or University. These grants will have their indirect costs flow through the VA, ACR, etc., and therefore are not on the original list. These grants are added.
- Sub-contracts and contracts are not included since all of this information is not available until late summer. This is generally about 3% of total amount.
- Multiple Principle Investigators (MPIs) are included only if the Contact PI is in another Department. Otherwise the grant would be counted 2 or more times for the same Institution.
- For reference, the Blue Ridge Report, from the Blue Ridge Institute for Medical Research, does not separate Radiation Oncology and they do not include the independent hospitals with Radiology Departments.